Thota, Ramya
3 papers on CoChatORCID 0000-0001-6538-9924
Most cited papers
- Verified
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 365
- Verified
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer
Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways
Cited by 22
- Verified · note
Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?
Thota, R., Maitra, A., & Berlin, J. D. (2017) · Pancreas
Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
Cited by 12
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free